Evidence map›Paper›PMID 28093088›Full record

Trial reportAlzheimer's research & therapy2017

Diagnostic impact of [

Marissa D Zwan, Femke H Bouwman, Elles Konijnenberg, Wiesje M van der Flier, Adriaan A Lammertsma, Frans R J Verhey, Pauline Aalten, Bart N M van Berckel, Philip Scheltens

Abstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives.European journal of nuclear medicine and molecular imaging · 2021
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Effectiveness of Florbetapir PET Imaging in Changing Patient Management.Dementia and geriatric cognitive disorders · 2017
    Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Amyloid PET and clinical management in a diverse, cognitively impaired population: The New IDEAS Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Observational
  11. A brief history of Aβ imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Incremental value of amyloid PET in a tertiary memory clinic setting in China.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  19. Article
  20. Clinical outcomes up to 9 years after [Alzheimer's research & therapy · 2023
    Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marissa D ZwanAlzheimer Center & Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. m.zwan@vumc.nl.
Femke H BouwmanAlzheimer Center & Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Elles KonijnenbergAlzheimer Center & Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Wiesje M van der FlierAlzheimer Center & Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Adriaan A LammertsmaDepartment of Radiology & Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.
Frans R J VerheySchool for Mental Health and Neuroscience, Alzheimer Centre Limburg, European Graduate School of Neuroscience EURON, Maastricht University, Maastricht, The Netherlands.
Pauline AaltenSchool for Mental Health and Neuroscience, Alzheimer Centre Limburg, European Graduate School of Neuroscience EURON, Maastricht University, Maastricht, The Netherlands.
Bart N M van BerckelDepartment of Radiology & Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.
Philip ScheltensAlzheimer Center & Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly-onset dementia patients often present with atypical clinical symptoms, hampering an accurate clinical diagnosis. The purpose of the present study was to assess the diagnostic impact of the amyloid-positron emission tomography (PET) imaging agent [

methodsThis prospective bi-center study included 211 patients suspected of early-onset dementia who visited a tertiary memory clinic. Patients were eligible with Mini Mental State Examination ≥ 18 and age at diagnosis ≤ 70 years and in whom the diagnostic confidence was <90% after routine diagnostic work-up. All patients underwent [

results[

conclusions[

trial registrationNederlands Trial Register NTR3743 . Registered 7 December 2012.

Indexed as

Aniline CompoundsBenzothiazolesFluorine RadioisotopesPositron-Emission TomographyRadiopharmaceuticalsAgedAge of OnsetBrainDementiaFemaleHumansMaleMiddle AgedProspective StudiesAniline CompoundsBenzothiazolesFluorine RadioisotopesflutemetamolRadiopharmaceuticalsAlzheimer’s diseaseAmyloidClinical practiceDementiaDiagnostic impactImagingPositron emission tomography

Identifiers

PMID28093088
PMCPMC5240413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.